Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study#

Research output

Research output per year 2019 2019 2019

• 1 Article

Research output per year

Research output per year

Search results

• 2019

  Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study^#

  Gamez, J., Salvadó, M., Reig, N., Suñé, P., Casasnovas, C., Rojas-Garcia, R. & Insa, R., 3 Apr 2019, In: Amyloid. 26, 2, p. 74-84 11 p.

  Research output: Contribution to journal › Article › Research › peer-review

  • Proof of Concept Study 100%
  • Transthyretin 100%
  • Asymptomatic Carriers 100%
  • Tolcapone 100%
  • Catechol-O-methyltransferase Inhibitors 100%

  52   Link opens in a new tab Citations (Scopus)